FY2027 EPS Estimates for Immunocore Lowered by HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – HC Wainwright reduced their FY2027 earnings estimates for shares of Immunocore in a research report issued to clients and investors on Friday, November 7th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.93 for the year, down from their previous forecast of $1.12. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore’s FY2028 earnings at $4.10 EPS and FY2029 earnings at $7.55 EPS.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.32. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The company had revenue of $135.80 million for the quarter, compared to analysts’ expectations of $137.29 million. During the same period last year, the firm earned $0.17 EPS. Immunocore’s revenue for the quarter was up 29.2% compared to the same quarter last year.

Other equities research analysts have also issued reports about the stock. Guggenheim initiated coverage on shares of Immunocore in a report on Thursday, September 18th. They issued a “neutral” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research report on Wednesday, October 8th. Wells Fargo & Company initiated coverage on shares of Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective on the stock. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 4th. Finally, Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $60.89.

Immunocore Stock Up 6.0%

NASDAQ IMCR opened at $33.50 on Monday. Immunocore has a 52 week low of $23.15 and a 52 week high of $39.33. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $1.69 billion, a P/E ratio of -58.77 and a beta of 0.78. The stock’s 50-day moving average price is $33.83 and its 200-day moving average price is $33.20.

Institutional Trading of Immunocore

Several hedge funds have recently modified their holdings of IMCR. Envestnet Asset Management Inc. grew its holdings in shares of Immunocore by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 67,259 shares of the company’s stock valued at $1,996,000 after purchasing an additional 735 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Immunocore by 0.4% during the first quarter. Massachusetts Financial Services Co. MA now owns 460,751 shares of the company’s stock valued at $13,670,000 after purchasing an additional 1,706 shares during the last quarter. Assetmark Inc. lifted its position in Immunocore by 4.8% during the first quarter. Assetmark Inc. now owns 33,710 shares of the company’s stock valued at $1,000,000 after purchasing an additional 1,539 shares during the last quarter. Fiera Capital Corp grew its stake in shares of Immunocore by 3.2% in the 1st quarter. Fiera Capital Corp now owns 805,150 shares of the company’s stock worth $23,889,000 after buying an additional 25,186 shares in the last quarter. Finally, Primecap Management Co. CA increased its holdings in shares of Immunocore by 0.4% in the 1st quarter. Primecap Management Co. CA now owns 2,678,650 shares of the company’s stock worth $79,476,000 after buying an additional 10,100 shares during the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Immunocore

In related news, insider David M. Berman sold 22,532 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $35.67, for a total transaction of $803,716.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.40% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.